Ethylmalonate

Ethylmalonate

SCHEMBL5236397

CCC(C(=O)O)C(=O)O.[MgH2]

nearest known ligand 0.53

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 2/20 0.43
HDAC2 Q92769 2/20 0.43
CHRM1 P11229 1/20 0.43
AKR1A1 P14550 1/20 0.43
CHRM3 P20309 1/20 0.43
HTR2A P28223 1/20 0.43
HTR2C P28335 1/20 0.43
ADRA1A P35348 1/20 0.43
HRH1 P35367 1/20 0.43
DRD3 P35462 1/20 0.43
SLC6A3 Q01959 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
CA2 P00918 1/20 0.42
MAPK1 P28482 1/20 0.42
FFAR3 O14843 2/20 0.41
SLC1A3 P43003 1/20 0.40
SLC1A2 P43004 1/20 0.40
SLC1A1 P43005 1/20 0.40
TP53 P04637 1/20 0.39
MEN1 O00255 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ethylmalonate SCHEMBL107241 0.96
Ethylmalonate SCHEMBL9765245 0.93 HDAC1 (0.43) HDAC1HDAC2CHRM1AKR1A1CHRM3
Ethylmalonate SCHEMBL29018396 0.93 HDAC1 (0.43) HDAC1HDAC2CHRM1AKR1A1CHRM3
Ethylmalonate SCHEMBL27701081 0.93 HDAC1 (0.43) HDAC1HDAC2CHRM1AKR1A1CHRM3
Ethylmalonate SCHEMBL83437 0.93 HDAC1 (0.43) HDAC1HDAC2CHRM1AKR1A1CHRM3
Ethylmalonate SCHEMBL108554 0.93 HDAC1 (0.43) HDAC1HDAC2CHRM1AKR1A1CHRM3
Ethylmalonate SCHEMBL108039 0.93 HDAC1 (0.43) HDAC1HDAC2CHRM1AKR1A1CHRM3
Ethylmalonate SCHEMBL9118935 0.93 HDAC1 (0.43) HDAC1HDAC2CHRM1AKR1A1CHRM3
Ethylmalonate SCHEMBL3157979 0.93 HDAC1 (0.43) HDAC1HDAC2CHRM1AKR1A1CHRM3
Ethylmalonate SCHEMBL28314280 0.93 HDAC1 (0.43) HDAC1HDAC2CHRM1AKR1A1CHRM3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110172019-A The metal salt of malonic acid as the nucleating additive for crystalline thermoplastic 印度石油有限公司 2019-08-27 CN claimed
EP-4631955-A1 PURIFICATION METHOD AND PRODUCTION METHOD OF CYCLIC PEPTIDE CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2025-10-15 EP disclosed
WO-2024143514-A1 PURIFICATION METHOD AND PRODUCTION METHOD OF CYCLIC PEPTIDE 中外製薬株式会社 2024-07-04 WO disclosed
CN-116854744-A Synthesis and application of chiral spiro [ chromane-4, 1' -indan ] bidentate ligand iridium complex 南开大学 2023-10-10 CN disclosed
CN-116655691-A Synthesis and application of chiral spiro [ chromane-4, 1' -indan ] phosphite monophosphorus ligand 南开大学 2023-08-29 CN disclosed
US-11572384-B2 Unusual substrates of tubulin tyrosine ligase FORSCHUNGSVERBUND BERLIN E.V. (DE) 2023-02-07 US disclosed
US-11279733-B2 Peptide antibiotics THE UNIVERSITY OF QUEENSLAND (AU) 2022-03-22 US disclosed
CN-110172019-B Metal salts of malonic acid as nucleating additives for crystalline thermoplastics 印度石油有限公司 2022-03-04 CN disclosed
CN-109970697-B Synthesis method of chiral spiro [ chroman-4, 1' -indan ] molecule 南开大学 2021-10-12 CN disclosed
US-20200361994-A1 PEPTIDE ANTIBIOTICS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2020-11-19 US disclosed
US-6331548-B1 PREVENTION OR TREATMENT OF CYTOKINE RELATED DISEASES SUNTORY LIMITED (JP) 2001-12-18 US disclosed
CN-1268947-A Novel process for preparing 4-hydroxy-2-oxo-pyran derivatives as protease inhibitors UPJOHN CO (US) 2000-10-04 CN disclosed
EP-0990654-A1 SUBSTITUTED CYCLOBUTYLAMINE DERIVATIVES DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2000-04-05 EP disclosed
EP-0978516-A1 1-CYCLOALKYL-1,8-NAPHTHYRIDIN-4-ONE DERIVATIVES WITH PHOSPHODIESTERASE IV INHIBITORY ACTIVITY SUNTORY LIMITED (JP) 2000-02-09 EP disclosed
CN-1049219-C Fused heteroaromatic cyclopentene derivative having endothelin-antagonist activity BANYU PHARMA CO LTD (JP) 2000-02-09 CN disclosed
US-5948786-A BLOCKING TUMOR NECROSIS FACTOR SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 1999-09-07 US disclosed
EP-0892795-A1 PIPERIDINYLPYRAMIDINE DERIVATIVES SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 1999-01-27 EP disclosed
WO-1997038992-A1 PIPERIDINYLPYRAMIDINE DERIVATIVES SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 1997-10-23 WO disclosed
CN-1129448-A Fused heteroaromatic cyclopentene derivative having endothelin-antagonist activity BANYU PHARMA CO LTD (JP) 1996-08-21 CN disclosed
CN-1095718-A Condensed heterocycle compound, their preparation and purposes TAKEDA CHEMICAL INDUSTRIES LTD (JP) 1994-11-30 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11572384-B2 Unusual substrates of tubulin tyrosine ligase TTL, TUBA1C, TUBB6 HDAC1 3887/4885HDAC2 4483/4885CHRM1 4792/4885
US-20200361994-A1 PEPTIDE ANTIBIOTICS NGLY1, VIP, PEPD HDAC1 3213/4885HDAC2 3989/4885CHRM1 4873/4885
US-11279733-B2 Peptide antibiotics NGLY1, VIP, PEPD HDAC1 3213/4885HDAC2 3989/4885CHRM1 4873/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.